1. Home
  2. PHAR vs EVLV Comparison

PHAR vs EVLV Comparison

Compare PHAR & EVLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHAR
  • EVLV
  • Stock Information
  • Founded
  • PHAR 1988
  • EVLV 2013
  • Country
  • PHAR Netherlands
  • EVLV United States
  • Employees
  • PHAR N/A
  • EVLV N/A
  • Industry
  • PHAR Biotechnology: Pharmaceutical Preparations
  • EVLV Computer peripheral equipment
  • Sector
  • PHAR Health Care
  • EVLV Technology
  • Exchange
  • PHAR Nasdaq
  • EVLV Nasdaq
  • Market Cap
  • PHAR 731.1M
  • EVLV 671.9M
  • IPO Year
  • PHAR N/A
  • EVLV N/A
  • Fundamental
  • Price
  • PHAR $10.42
  • EVLV $5.72
  • Analyst Decision
  • PHAR Strong Buy
  • EVLV Buy
  • Analyst Count
  • PHAR 3
  • EVLV 2
  • Target Price
  • PHAR $30.00
  • EVLV $6.50
  • AVG Volume (30 Days)
  • PHAR 3.5K
  • EVLV 2.7M
  • Earning Date
  • PHAR 07-31-2025
  • EVLV 08-14-2025
  • Dividend Yield
  • PHAR N/A
  • EVLV N/A
  • EPS Growth
  • PHAR N/A
  • EVLV N/A
  • EPS
  • PHAR N/A
  • EVLV N/A
  • Revenue
  • PHAR $320,708,000.00
  • EVLV $113,691,000.00
  • Revenue This Year
  • PHAR $13.31
  • EVLV $26.46
  • Revenue Next Year
  • PHAR $7.68
  • EVLV $18.80
  • P/E Ratio
  • PHAR N/A
  • EVLV N/A
  • Revenue Growth
  • PHAR 24.13
  • EVLV 36.70
  • 52 Week Low
  • PHAR $6.65
  • EVLV $2.04
  • 52 Week High
  • PHAR $12.61
  • EVLV $6.45
  • Technical
  • Relative Strength Index (RSI)
  • PHAR 48.06
  • EVLV 48.08
  • Support Level
  • PHAR $9.99
  • EVLV $5.55
  • Resistance Level
  • PHAR $10.49
  • EVLV $6.06
  • Average True Range (ATR)
  • PHAR 0.33
  • EVLV 0.23
  • MACD
  • PHAR -0.11
  • EVLV -0.08
  • Stochastic Oscillator
  • PHAR 29.19
  • EVLV 6.18

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

About EVLV Evolv Technologies Holdings Inc.

Evolv Technologies Holdings Inc offers an AI-based touchless security screening. Its touchless security screening systems use artificial intelligence software, cloud services, and sensors to reliably detect dangerous weapons while ignoring harmless items like cell phones, laptops, and keys. It offers products for purchase under a multi-year security-as-a-service subscription pricing model that delivers ongoing value to customers, generates predictable revenue, and creates expansion and upsell opportunities. The firm operates in a single segment that develops, manufactures, markets, and sells security screening products and specific services. Its products are used in different industries such as casinos, industrial workplaces, schools, and ticketed venues.

Share on Social Networks: